Antimicrobial resistance is a looming threat for modern medicine, but Australian biotech Recce Pharmaceuticals might have found a solution in its broad-spectrum synthetic antibiotic. Chloe Kent speaks to Recce executive director of regulatory affairs Michele Dilizia about the idea behind this novel approach.